Please login to the form below

Not currently logged in
Email:
Password:

Ninlaro

This page shows the latest Ninlaro news and features for those working in and with pharma, biotech and healthcare.

Takeda can't sway NICE on oral myeloma therapy Ninlaro

Takeda can't sway NICE on oral myeloma therapy Ninlaro

Takeda can't sway NICE on oral myeloma therapy Ninlaro. Drug not recommended for NHS use in England and Wales. ... Ninlaro was approved by the EMA last November, becoming the first orally-active proteasome inhibitor to be registered in Europe.

Latest news

More from news
Approximately 4 fully matching, plus 9 partially matching documents found.

Latest Intelligence

  • Forging a path in specialty care Forging a path in specialty care

    Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics